BMS-1 from MedChemExpress

Product Specs
ItemBMS-1
CompanyMedChemExpress
Price $99.00Supplier Page View Company Product Page
Catalog NumberHY-19991
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.71%
TypeChemical
Molecular Weight475.58
FormulaC₂₉H₃₃NO₅
Research AreaInflammation/Immunology; Cancer

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug deliveryBreast Cancer ResearchFebruary 26, 2026Jinjin Chen, Liang Ma, Ming Yin, Jian Sun, Yunhao Sunnanoprecipitation method. In this process, Fe³⁺ (from FeCl₃), BMS-1 [PD-1/PD-L1 inhibitor, purity 98%, Cat. No. HY-19991, MedChemExpress (MCE)], and R848 (Resiquimod, purity 98%, Cat. No. HY-13740, MCE) were mixed in appropriate

(2) Walnut Green Husk Polysaccharide Improve Gut Microbiota and Alleviate Intestinal Inflammation Caused by Immune Checkpoint InhibitorsCurrent Issues in Molecular BiologyFebruary 10, 2026Yunting Deng, Yannan Zhang, Bowen Yan, Jinhai Huo, Weiming WangEnzyme-linked Biotechnology Co., Ltd., Shanghai, China), PD-1 inhibitors (MCE, Monmouth Junction, NJ, USA, HY-19991), corn oil (Biyuntian Biotechnology Co., Ltd., Shanghai, China), bicinchoninic acid (BCA) protein concentration

(3) TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinomaRespiratory researchJune 11, 2024Liu Z, Lu Q, Zhang Z, Feng Q, Wang X.ShTMPRSS2 mice treated with 150 U/L PD1/PDL1 inhibitor BMS-1 (concentration 500 mg/mL; i.p.) (MCE Cat. No. HY-19991) every 3 days. The tumors were isolated from mice after 15 days. Tumor volumes did not exceed the maximum

(4) The regulation of the PD-1/PD-L1 pathway in imiquimod-induced chronic psoriasis itch and itch sensitization in mouseMolecular PainMay 3, 2024Zhehao Xu, Yue Wang, Changcheng Jiang, Zhengwei Wang, YongFeng Cheng, Manli Fan(San Francisco, CA, USA). The small molecule PD-1/PD-L1 inhibitors, BMS-1 (50 μg in 50 µL of saline, HY-19991) and BMS-202 (50 μg in 50 µL of saline, HY-19745) and PLX5622 in AIN-76A Diet (contains 1200 mg of PLX5622

(5) Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophagesJournal of experimental & clinical cancer research : CRJanuary 3, 2022Chen Y, Liu Y, Wang Y, Chen X, Wang C, Chen X, Yuan X, Liu L, Yang J, Zhou X.cardiotoxicity, and may provide a potential therapeutic target. Methods Chemicals and reagents BMS-1 (HY-19991) and sodium butyrate (HY-B0350A) were purchased from MedChemExpress (Monmouth Junction, New Jersey,

(6) Integrated Analysis of Ferroptosis-Related Biomarker Signatures to Improve the Diagnosis and Prognosis Prediction of Ovarian CancerFrontiers in cell and developmental biologyJanuary 1, 2021Wang H, Cheng Q, Chang K, Bao L, Yi X.96-well plates, 24 h later cells were treated with cisplatin, paclitaxel, or BMS-1 (HY-17394, HY-B0015, HY-19991, MCE, China) for 24 h. Treatment drug concentrations were as follows: cisplatin at doses of 0, 5, 10,

(7) KALRN mutations promote antitumor immunity and immunotherapy response in cancerJournal for immunotherapy of cancerOctober 1, 2020Li M, Ma Y, Zhong Y, Liu Q, Chen C, Qiang L, Wang X.mice were treated with 100 U/L PD1/PDL1 inhibitor BMS-1 (concentration 500 mg/mL; i.p.) (MCE Cat. No. HY-19991) every 3 days. The tumors were isolated from mice after 15 days. Tumor volumes did not exceed the maximum

(8) Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cellsCarcinogenesisSeptember 18, 2019Zhao Y, Jia Y, Shi T, Wang W, Shao D, Zheng X, Sun M, He K, Chen L.

(9) Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune responseVaccineApril 3, 2019Zhang H, Jia E, Xia W, Lv T, Lu C, Xu Z, Zhu W.

(10) Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapyJournal of drug targetingMarch 1, 2019Li K, Tian H.

Be the First to Write a Review!

Description

MedChemExpress

Citations (10)

Reviews

BMS-1 from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map